Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial
| Autor: | Orazio Caffo, Cosimo Sacco, Enzo Galligioni, Fable Zustovich, Annamaria Fariello, Teodoro Sava, F. Valduga, Evi Comploj, Gianluigi Cetto, Romana Segati |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Randomization Urology Docetaxel law.invention chemistry.chemical_compound Prostate cancer Randomized controlled trial law Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over business.industry Prostatic Neoplasms Cancer Middle Aged Prostate-Specific Antigen medicine.disease Survival Analysis Nitrogen mustard Surgery Clinical trial Treatment Outcome chemistry Estramustine Taxoids business medicine.drug |
| Zdroj: | BJU International. 102:1080-1085 |
| ISSN: | 1464-410X 1464-4096 |
| Popis: | OBJECTIVE To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS Patients with progressive HRPC were randomized to receive docetaxel 70 mg/m2 on day 1 (arm A), or docetaxel 70 mg/m2 on day 2 plus oral EP three times daily, at a total daily dose of 840 mg, on days 1–5 (arm B). The primary objective of the trial was to evaluate the activity of the treatments in terms of the response in prostate-specific antigen (PSA) level. RESULTS Forty-five of the 49 patients centrally randomized to arm A and 44 of the 46 in arm B were evaluable for activity. The PSA level decreased by ≥50% in 40% of the patients in arm A and in 75% of those in arm B. The median time to PSA progression was 20 weeks in arm A and 30 weeks in arm B. The patients in arm B had an improvement in pain over time. CONCLUSION These data support the existence of a possible advantage in combining docetaxel and EP, which should be verified in a specific randomized phase III study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|